Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Incyte Corp (INCY)

76.02   -2.54 (-3.23%) 03-03 17:03
Open: 78.325 Pre. Close: 78.56
High: 78.58 Low: 75.58
Volume: 1,363,411 Market Cap: 16,713M
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited, as well as a clinical collaboration with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 78.614 - 79.142 79.142 - 79.58
Low: 74.582 - 75.089 75.089 - 75.51
Close: 75.277 - 76.1 76.1 - 76.782

Technical analysis

as of: 2021-03-03 4:41:39 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 105.46     One year: 116.08
Support: Support1: 75.58    Support2: 62.88
Resistance: Resistance1: 90.29    Resistance2: 99.38
Pivot: 80.89
Moving Average: MA(5): 78.26     MA(20): 83.43
MA(100): 86.96     MA(250): 90.65
MACD: MACD(12,26): -3.33     Signal(9): -2.79
Stochastic oscillator: %K(14,3): 10.17     %D(3): 11.78
RSI: RSI(14): 31.70
52-week: High: 110.37  Low: 62.48  Change(%): -3.3
Average Vol(K): 3-Month: 120043  10-Days: 153030

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
INCY has closed above bottom band by 3.7%. Bollinger Bands are 6.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 03 Mar 2021
Eli Lilly/Incyte's Baricitinib Shows Benefit In Patchy Hair Loss Disorder - Benzinga

Fri, 26 Feb 2021
Insider Buying: The Incyte Corporation (NASDAQ:INCY) Chairman Just Bought 5.9% More Shares - Simply Wall St

Wed, 24 Feb 2021
Incyte Corporation (INCY) Stock Falls -2.36% This Week; Should You Buy? - InvestorsObserver

Tue, 23 Feb 2021
Is Incyte Corporation (INCY) a Bad Choice in Biotechnology Tuesday? - InvestorsObserver

Thu, 18 Feb 2021
Incyte Corporation (INCY) Stock: Buy, Hold, or Sell? - InvestorsObserver

Tue, 16 Feb 2021
Incyte: Another Buy Opportunity - Seeking Alpha

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 219
Shares Float (M) 185
% Held by Insiders 1.34
% Held by Institutions 94.48
Shares Short (K) 4,530
Shares Short P. Month (K) 4,760

Stock Financials

EPS -1.550
EPS Est This Year -0.810
EPS Est Next Year 0.420
Book Value (p.s.) 10.920
Profit Margin -13.62
Operating Margin -12.65
Return on Assets (ttm) -6.0
Return on Equity (ttm) -13.9
Qtrly Rev. Growth 12.5
Gross Profit (p.s.) 4.066
Sales Per Share 11.233
EBITDA (p.s.) -1.178
Qtrly Earnings Growth
Operating Cash Flow (M) -100
Levered Free Cash Flow (M) -89

Stock Valuations

PE Ratio -49.05
PEG Ratio
Price to Book value 6.96
Price to Sales 6.77
Price to Cash Flow -165.99

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.